Stockscreener 앱 받기
22.29
0.63%
0.14
시간 외 거래:
22.35
0.06
+0.27%
전일 마감가:
$22.15
열려 있는:
$22.28
하루 거래량:
2.49M
Relative Volume:
0.70
시가총액:
$16.56B
수익:
$220.00K
순이익/손실:
$-746.08M
주가수익비율:
-22.13
EPS:
-1.0074
순현금흐름:
$-211.81M
1주 성능:
+7.89%
1개월 성능:
-14.20%
6개월 성능:
+28.70%
1년 성능:
+17.81%
1일 변동 폭
$21.29
$22.63
1주일 범위
$20.29
$22.63
52주 변동 폭
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
305-203-2034
주소
601 BRICKELL KEY DRIVE, MIAMI
SMMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
22.29 | 16.45B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.28 | 103.30B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
583.24 | 62.05B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.58 | 59.25B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
797.35 | 48.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
341.62 | 37.84B | 4.56B | -176.77M | 225.30M | -1.7177 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Barclays | Underweight |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Neutral |
| 2025-07-01 | 개시 | UBS | Buy |
| 2025-06-11 | 개시 | Leerink Partners | Underperform |
| 2025-03-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 개시 | Evercore ISI | Outperform |
| 2025-02-28 | 개시 | Goldman | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-05-07 | 개시 | Citigroup | Buy |
| 2024-03-26 | 개시 | Stifel | Buy |
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
How to use Fibonacci retracement on Summit Therapeutics Inc.Gap Up & Community Verified Trade Signals - newser.com
1 Monster Stock in the Making to Buy and Hold - Yahoo Finance
Published on: 2025-10-05 07:31:28 - newser.com
How to monitor Summit Therapeutics Inc. with trend dashboards2025 Market Sentiment & Community Driven Trade Alerts - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - PR Newswire
How the European Spotlight on Ivonescimab’s Phase III Data Could Shape Summit Therapeutics (SMMT) - simplywall.st
Is Summit Therapeutics Inc. forming a bottoming baseJuly 2025 Rallies & Real-Time Volume Analysis - newser.com
Is Summit Therapeutics Inc. stock supported by strong cash flowsRisk Management & Safe Entry Zone Identification - newser.com
A Look at Summit Therapeutics (SMMT) Valuation Following Phase III Trial Setback and Legal Investigation - Yahoo Finance
H.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab Milestones - MSN
Alpha Buying: The 3 Stocks That Just Got This $1 Million Vote of Confidence - Benzinga
Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025 - Yahoo Finance
Will Summit Therapeutics Inc. stock continue dividend increasesJuly 2025 Catalysts & Verified Momentum Stock Ideas - newser.com
Published on: 2025-09-30 03:00:28 - newser.com
Published on: 2025-09-30 00:09:58 - newser.com
Will Summit Therapeutics Inc. stock gain from lower inflationWeekly Profit Recap & Pattern Based Trade Signal System - newser.com
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug - MSN
What analysts say about Summit Therapeutics Inc stockResistance Zone Identification & Free Stock Education Platform for New Investors - earlytimes.in
Summit Therapeutics Inc Stock Analysis and ForecastAI-Driven Market Analysis & Learn From the Strategies of Institutions - earlytimes.in
Positive Catalyst Watch Boosts SMMT Stock Outlook - GuruFocus
Barclays Maintains Summit Therapeutics(SMMT.US) With Sell Rating, Maintains Target Price $13 - 富途牛牛
Summit Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
First-Ever PD-1 Therapy Superiority: Summit's Ivonescimab Achieves Breakthrough in Advanced Lung Cancer Trial - Stock Titan
Weekly Analysts’ Ratings Updates for Summit Therapeutics (SMMT) - Defense World
Voya Investment Management LLC Sells 34,041 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics PLC $SMMT Shares Sold by Wealth Management Partners LLC - MarketBeat
Barclays Begins Coverage on Summit Therapeutics (NASDAQ:SMMT) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Summit Therapeutics Inc. (SMMT) And Encourages Shareholders to Connect - ACCESS Newswire
Summit Therapeutics Inc. stock chart pattern explainedWeekly Profit Recap & Accurate Intraday Trade Tips - newser.com
Primer: Summit Therapeutics (SMMT US)Sep 2025 - Smartkarma
Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated at Barclays - MarketBeat
Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China - MSN
Will Summit Therapeutics Inc. benefit from macro trendsJuly 2025 Fed Impact & High Conviction Investment Ideas - newser.com
Summit Therapeutics (NASDAQ:SMMT) Given Buy Rating at HC Wainwright - MarketBeat
Aug Catalysts: Is Summit Therapeutics Inc benefiting from innovation trendsTrade Entry Summary & Reliable Price Breakout Signals - خودرو بانک
Summit Therapeutics Inc (SMMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.07%
0.86%
자본화:
|
볼륨(24시간):